<DOC>
	<DOCNO>NCT02405676</DOCNO>
	<brief_summary>The purpose study test whether add 4 injection rituximab increase intensity chemotherapy regimen advance patient improve EFS compare historical study CCCG-NHL-2009 .</brief_summary>
	<brief_title>BNHL-2015 Children Adolescents China</brief_title>
	<detailed_description>In previous study ( CCCG-NHL-2010 ) , two-year EFS 100 % Stage I , 91.3 % ± 6.1 % Stage II , 75.8 % ± 4.4 % Stage III , 56.3 % ± 13.5 % Stage IV , 36.4 % ± 14.5 % B-AL , respectively . To improve survival pediatric patient B-NHL/B-AL , investigator launch new study China . Compared previous treatment regimen ( CCCG-2009 ) , patient stage III LDH &gt; 4 time NL , stage IV B-AL stratify R4 . The dose methotrexate increase 5000mg/m2 patient R3 R4 ( previously 3000mg/m2 ) . Four injection rituximab add chemotherapy patient R4 . Our aim test whether add rituximab high dose methotrexate ( 5000mg/m2 ) would improve 2-year EFS patient advance group .</detailed_description>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Histology cytologically confirm matureBcell NHL/AL ( Burkitt , DLBCL , PMLBL , aggressive mature Bcell NHL non specify specifiable ) Able comply schedule followup management toxicity Signed inform consent Follicular lymphoma , MALT nodular marginal zone include therapeutic study Patients congenital immunodeficiency , chromosomal breakage syndrome , prior organ transplantation , previous malignancy type , know positive HIV serology . Evidence pregnancy lactation period . Past current anticancer treatment except corticosteroid le one week . Exclusion criterion related rituximab : Tumor cell negative CD20 . Prior exposure rituximab . Hepatitis B carrier status history HBV positive serology .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>non-Hodgkin</keyword>
	<keyword>B-lymphocytes</keyword>
	<keyword>Child</keyword>
	<keyword>Multicenter study</keyword>
</DOC>